Pharma · Private company
Novartis Gene Therapies
Track this companyFree. Adds Novartis Gene Therapies to your Dealase workspace and tells you when its record changes.
Clinical trials62 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- onasemnogene abeparvovec-xioiPhase 3 · Spinal Muscular AtrophyClinicalTrials.gov · fetched Nov 12, 2026
- Onasemnogene Abeparvovec-xioiPhase 3 · SMA - Spinal Muscular AtrophyClinicalTrials.gov · fetched Nov 12, 2026
- Onasemnogene Abeparvovec-xioiPhase 3 · Spinal Muscular Atrophy Type IClinicalTrials.gov · fetched Nov 12, 2026
- AVXS-101Phase 1 · Spinal Muscular Atrophy 1ClinicalTrials.gov · fetched Nov 12, 2026
- Onasemnogene Abeparvovec-xioiSpinal Muscular Atrophy 1ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioiPHASE3 · ACTIVE_NOT_RECRUITING · started Feb 10, 2020ClinicalTrials.gov NCT04042025 · fetched Nov 12, 2026
- Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2PHASE3 · COMPLETED · started Apr 2, 2018ClinicalTrials.gov NCT03505099 · fetched Nov 12, 2026
- Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular AtrophyPHASE1 · TERMINATED · started Dec 14, 2017ClinicalTrials.gov NCT03381729 · fetched Nov 12, 2026
- Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1PHASE3 · COMPLETED · started Oct 24, 2017ClinicalTrials.gov NCT03306277 · fetched Nov 12, 2026
- Long-Term Follow-up Study for Patients From AVXS-101-CL-101ACTIVE_NOT_RECRUITING · started Sep 21, 2017ClinicalTrials.gov NCT03421977 · fetched Nov 12, 2026
- Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1PHASE1 · COMPLETED · started May 5, 2014ClinicalTrials.gov NCT02122952 · fetched Nov 12, 2026